New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:39 EDTGALT, LJPCGalectin drug showed no difference from placebo, The Street reports
Galectin's (GALT) GR-MD-02 showed no difference from placebo across most efficacy biomarkers in a phase I study of nonalcoholic steatohepatitis, The Street's Adam Feuerstein reports. The stock is trading down 50% today to $7.24 while La Jolla (LJPC), which is developing a similar drug to treat NASH, is down 13%. Reference Link
News For GALT;LJPC From The Last 14 Days
Check below for free stories on GALT;LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:07 EDTGALTGalectin Therapeutics issued U.S. patent for GR-MD-02
Subscribe for More Information
September 12, 2014
15:12 EDTGALTGalectin Therapeutics says in ongoing talks with large pharma companies
Subscribe for More Information
September 11, 2014
07:25 EDTGALTAegis to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use